Exosomes
Extracellular vesicles (EVs), MSC-conditioned media, plant exosomes
Exosomes (Extracellular vesicles (EVs), MSC-conditioned media, plant exosomes) is a healing & recovery research compound. Exosomes are nanoscale (30–150 nm) lipid-bilayer vesicles that cells release to talk to each other. They carry a cargo — miRNA, mRNA, proteins, lipids — and when a neighboring cell takes one up, that cargo changes what the recipient cell does. The cosmetic premise is that vesicles harvested from stem-cell-conditioned media or from plants deliver pro-regenerative signals to skin. The mechanism is real biology and is under serious investigation. The problem is not the concept, it is everything downstream of it.
Exosomes quick facts
| Reported research dose | No established dose — product potency is not standardized |
| Route | Topical (cosmetic) — injectable use is not approved |
| Frequency | As directed (topical) |
| Half-life | Not characterized for topical products |
| Forms | Topical |
| Evidence level | Preclinical and in-vitro; no standardized human topical evidence. Regulators have warned about unapproved injectable exosome products. |
Be more skeptical here than anywhere else in this section. Three specific problems, none of them solved. First, there is no standard: 'exosome serum' describes the claimed source, not a dose, a particle count or a cargo, so two products with the same label can be entirely different things. Second, exosomes are large, fragile and easily destroyed by processing and storage — many products have been found to contain few intact vesicles. Third, penetration of an intact 30–150 nm vesicle through healthy skin is not established, which is why most credible use is immediately after microneedling or laser, when the barrier is deliberately breached. Separately and importantly: injected exosome products are not approved, and regulators including the FDA have issued warnings after adverse events. Topical cosmetic use is a different risk picture from injection — do not treat them as the same thing. None of this means exosomes do nothing. It means nobody can currently tell you what a given bottle contains or what it does, and you should price that uncertainty in.
How Exosomes works
Exosomes are nanoscale (30–150 nm) lipid-bilayer vesicles that cells release to talk to each other. They carry a cargo — miRNA, mRNA, proteins, lipids — and when a neighboring cell takes one up, that cargo changes what the recipient cell does. The cosmetic premise is that vesicles harvested from stem-cell-conditioned media or from plants deliver pro-regenerative signals to skin. The mechanism is real biology and is under serious investigation. The problem is not the concept, it is everything downstream of it.
Proposed benefits
Marketed for skin rejuvenation, post-procedure recovery and hair density. Claims currently run well ahead of data.
Where to get Exosomes
Buy Exosomes at Disguised Alpha →The evidence for Exosomes
Graded by what exists behind each claim.
✅ Clinically validated
- There is no clinical tier here worth the name, and that is the finding. No standardized controlled human data supports topical cosmetic exosome products. Regulators including the FDA have issued warnings about unapproved injectable exosome products following adverse events — which is a statement about safety oversight, not evidence of benefit.
📊 Correlative data
- Widely used in clinics immediately after microneedling or ablative laser, and practitioner reports of faster settling are common. Note the confound: that is precisely the setting where the skin barrier has been deliberately breached and where post-procedure recovery would be tracked closely anyway.
- Independent analyses of commercial products have repeatedly found particle counts and vesicle integrity far below label claims. Two bottles reading 'exosome serum' can contain substantially different things.
🧪 Theoretical / extrapolated
- Exosomes are 30–150 nm lipid-bilayer vesicles that cells use to signal to one another, carrying miRNA, mRNA, proteins and lipids. When a recipient cell takes one up, that cargo changes its behavior. The premise — deliver pro-regenerative signals to skin — is real biology under serious study.
- Three unsolved problems sit between that premise and a bottle. There is no standard: 'exosome' names a claimed source, not a dose, a particle count or a cargo. They are fragile: processing, storage and preservatives degrade them. And penetration of an intact vesicle through healthy stratum corneum is not established.
- Unproven is not the same as ineffective. But nobody can currently tell you what a given bottle contains or what it does, and that uncertainty should be priced in rather than assumed away.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Exosomes actually does
“Exosome” is not the name of a substance. It is a claim about where a vesicle came from — specifically, that it was formed inside a multivesicular body and released when that body fused with the plasma membrane. The international reporting standard is blunt about this: unless subcellular origin can be demonstrated, what you have is a broad population of extracellular vesicles, not exosomes specifically, and the recommended term is EV Welsh 2024. Almost no product sold as an exosome serum has demonstrated subcellular origin. So the word on the bottle is, in the field's own terms, a category error before you get to the pharmacology.
The underlying biology is real and worth stating properly. Cells release lipid-bilayer vesicles roughly 30 to 150 nm across carrying microRNA, messenger RNA, protein and lipid. A recipient cell takes one up and its behavior changes, because the cargo arrives packaged and protected rather than diluted into serum. That is a genuine signaling channel under serious investigation Perocheau 2021. The problem on this page is not the concept. It is everything between the concept and the vial.
What is in the vial is decided by the isolation method, not by the cell. Take one batch of conditioned medium and split it: ultracentrifugation, precipitation, size-exclusion and immunoaffinity give different yields and different purities from the identical starting material Patel 2019. “Derived from stem-cell conditioned media” therefore describes the source and tells you nothing about the contents.
And the particle count on the label is instrument-dependent by an order of magnitude. Arab 2021 put the same EV preparations through four orthogonal single-particle platforms. Microfluidic resistive pulse sensing and nanoflow cytometry returned similar counts. Nanoparticle tracking analysis — the cheap, common method — read approximately one order of magnitude lower for EVs, though not for synthetic beads, and reported a mode diameter above 100 nm where the other platforms saw a population dominated by smaller particles. All of them lost sensitivity below about 60 nm. A single-particle interferometric platform could not be used to estimate concentration at all. So “10 billion particles” is a number that changes tenfold with the machine that produced it, and no consumer product states the machine.
What the reporting standard actually asks for. MISEV2023 asks that an EV preparation be quantified by particle number and protein content, characterized by at least one transmembrane or GPI-anchored marker and at least one cytosolic marker, and shown to be depleted of the non-vesicular co-isolates appropriate to its source — lipoproteins, soluble protein, ribonucleoprotein complexes Welsh 2024. Those four numbers are the difference between a characterized preparation and a liquid. Ask any vendor for them. The absence of an answer is the answer.
Cell, rodent, human — and where it stops
In cells: strong. EV uptake and functional cargo transfer between cells is established biology, reproduced across many systems Perocheau 2021.
In rodents, intravenously: this is where the fantasy of a circulating therapeutic dies. Takahashi 2013 labeled B16-BL6 melanoma exosomes with a Gaussia-luciferase–lactadherin fusion protein and injected them into the tail vein of mice. Pharmacokinetic analysis of the blood concentration–time curve gave a half-life of approximately 2 minutes; little luciferase activity remained in serum at 4 hours; and imaging showed the signal going first to the liver, then to the lungs. Species: mouse. Route: intravenous. That is the only well-characterized systemic pharmacokinetic profile the field has, and it says vesicles are cleared, not distributed.
In humans, topically: no standardized evidence exists. Not ‘limited’. There is no product with a stated particle count, a stated cargo, a stated dose and a randomized outcome. Perocheau 2021, reviewing the clinical position of the whole field, titles itself with the question — are we there yet — and the answer for cosmetic topical use is that the question has not been asked properly.
In humans, injected: a regulator has already had to intervene. On 6 December 2019 the FDA issued a public safety notification after multiple reports of serious adverse events in patients in Nebraska who received products marketed as containing exosomes, and stated plainly that there are currently no FDA-approved exosome products US Food and Drug Administration 2019.
The obstacle, and it is physical. The stratum corneum passively admits small, moderately lipophilic molecules — the working rule of thumb in dermal delivery is a ceiling around 500 Da. A 30–150 nm vesicle is not a 500 Da molecule; it is a particle four to five orders of magnitude larger by mass. So either intact vesicles do not cross unbroken skin, or the mechanism is something else — lysed membrane lipid and protein acting as an ordinary emollient and signaling soup. This is why almost every credible topical protocol pairs the serum with microneedling or a post-laser skin surface: the marketing implies delivery, and the delivery is being done by the needle.
Exosomes pharmacokinetics — how much of it actually gets in
Half-life is listed as not characterized, and for once the arithmetic that bounds it is more useful than a number would be. There are three routes people use, and they fail differently.
Injected. The one real measurement: approximately 2 minutes in mouse blood after intravenous injection, with hepatic accumulation first and pulmonary second, and essentially nothing left in serum at 4 hours Takahashi 2013. The clearance route is the mononuclear phagocyte system — liver and spleen macrophages take up foreign particulate matter, which is what a vesicle is. That is hepatic clearance of a particle, not metabolism of a drug, and it does not saturate at cosmetic doses.
What degrades it. A vesicle is a bag of lipid holding protein and RNA, and each layer has its own enemy. Serum proteases strip the surface proteins that make uptake targeted; phospholipases and hydrolysis of the bilayer release the cargo into a compartment it was never meant to reach; extracellular RNases destroy naked microRNA in seconds once the membrane is gone. None of this needs a cytochrome. Freeze-thaw cycles and warm shipping do the same job before the product ever reaches a customer, which is why storage temperature is a potency question and not a housekeeping one.
The oral barrier is absolute enough to be worth one sentence. A swallowed vesicle meets stomach acid, bile salts that dissolve lipid bilayers by design, and pancreatic lipase across the gastrointestinal tract. Whatever survives that is not the particle that was sold. There is no evidence for oral exosome delivery in humans, and the first-principles case against it is strong.
The topical barrier is the one that matters commercially. Intact skin admits molecules; a 30–150 nm particle is not a molecule. The honest position is that a topical exosome product has an unknown and probably very small delivered fraction, that the delivered fraction is unmeasured for every product on the market, and that no product reports the two numbers — particle count and protein content — that would let anyone compute a dose Welsh 2024.
What would have to be true, and how you would know it was not
This is a cosmetic category with no blood read-out, so the honest falsification test is not a lab panel. It is three questions, and they are harder to satisfy than two markers would be.
What to watch. For a topical: post-procedure erythema duration and downtime after microneedling or laser, photographed under fixed lighting at the same time of day, against the same procedure without the serum on the contralateral side. That split-face design is the only version of this that is not confounded by the procedure itself, and it is available to anyone. For hair: terminal hair count in a tattooed 1 cm target area, not a subjective impression. What you should not watch is overall skin quality over a course of treatments, because the treatments work.
How long before it means anything. Erythema and downtime differences declare themselves within 72 hours of a single procedure. Anything about texture, pigment or fine lines needs a full epidermal turnover and then some — 12 weeks minimum, and collagen remodeling after a resurfacing procedure continues for 6 months, which means a 4-week before-and-after photograph is measuring the laser, not the serum.
What will fool you. Four things, in order of how often they do it. (1) The procedure. Microneedling and lasers work on their own; anything applied afterwards inherits the credit. (2) The vehicle. These serums are delivered in hyaluronic acid and humectants that visibly plump skin for hours regardless of cargo. (3) The photograph. Lighting, angle and hydration move apparent skin quality more than most actives do. (4) The label. A particle count with no instrument named is not comparable to any other particle count — nanoparticle tracking analysis alone reads about tenfold lower than orthogonal methods on the same sample Arab 2021.
The one situation with a real blood read-out. If an unapproved exosome product has been injected, the relevant measurements are not cosmetic. A CBC with differential and an hs-CRP, plus blood cultures if there is fever, within 24 to 72 hours of feeling unwell — because what the regulator recorded in this category was serious adverse events after injection of an unlicensed biologic US Food and Drug Administration 2019, which makes fever or spreading redness a sterility question before it is a pharmacology one.
What nobody has tested yet
Nobody has published a MISEV-compliant characterization of products bought off the shelf. That is the missing paper, and it is not hard: buy ten retail “exosome” serums, run each for particle number by two orthogonal platforms, total protein, the particle-to-protein ratio, at least one transmembrane and one cytosolic EV marker, and the non-EV co-isolate markers appropriate to the source Welsh 2024 Arab 2021. Publish the table. One afternoon of instrument time per sample would tell consumers more than the entire marketing literature of this category.
Nobody has shown that an intact vesicle crosses intact human skin. The experiment is standard dermatology: fluorescently labeled EVs on human skin explants in Franz diffusion cells, confocal imaging of depth of penetration, with and without microneedling, and a lysed-vesicle control to separate cargo delivery from membrane lipid. Until that is done, every topical claim assumes a delivery step that has never been demonstrated.
There is no potency assay, and that is the deepest gap. A dose requires a unit. Particles per milliliter is not a unit of activity — it counts objects without asking what is in them. A functional assay — a defined recipient cell line, a defined reporter of the pathway the product claims to activate, a dose-response curve — would turn ‘exosomes’ from a source claim into a measurable intervention. Nobody sells one, and nobody is required to.
And nobody has compared sources head to head. Mesenchymal-stem-cell conditioned media, amniotic and umbilical tissue, and plant-derived vesicles are marketed interchangeably under one word while being three different biological materials. A single study running all three through the same characterization and the same functional assay would establish whether the word is describing one thing or three.
Exosomes — its own safety story, not its class's
The class safety framing does not apply here, because the hazard is manufacturing, not pharmacology. On 6 December 2019 the FDA issued a public safety notification following multiple reports of serious adverse events in patients in Nebraska given products marketed as containing exosomes, and stated that there are currently no FDA-approved exosome products US Food and Drug Administration 2019. The notification describes the events as serious and does not characterize them further, which is itself the point: a biologic prepared without release testing and injected into a person is a sterility and endotoxin problem first and a mechanism-of-action question a distant second.
The two failure modes point in opposite directions, and both are real. If the product contains no intact vesicles — plausible, given how easily bilayers are destroyed by processing, freeze-thaw and warm shipping — you have paid for an expensive emollient, and the risk is only your money. If the product does contain functional vesicles, then by the mechanism it is sold on it is delivering microRNA and protein that change what recipient cells do, from a donor cell line you cannot see, with no cargo manifest. You cannot have the efficacy argument without the second risk; they are the same claim.
Route changes the risk category completely. A topical applied to intact skin is a low-risk cosmetic whose main problem is that it probably does not get in. The same vial injected, microneedled into an open wound bed, or nebulized is an unapproved biologic entering tissue, and that is the exact configuration the FDA notification was written about US Food and Drug Administration 2019. The serum did not change; the regulatory and clinical situation changed entirely.
What to ask, in one sentence. Particle count with the instrument named, protein content, the particle-to-protein ratio, the EV markers detected and the non-EV markers excluded, the source cell and its passage number, and the sterility and endotoxin results Welsh 2024. Seven items, all of which a legitimate manufacturer already measures. In this market almost nobody will give you even two of them, and that refusal is more informative than any before-and-after photograph.
Sources read for this page
- Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.. J Extracell Vesicles 2024 · PMID 38326288
- Arab T. Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms.. J Extracell Vesicles 2021 · PMID 33850608
- Patel GK. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications.. Sci Rep 2019 · PMID 30926864
- Takahashi Y. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection.. J Biotechnol 2013 · PMID 23562828
- Perocheau D, Touramanidou L, Gurung S, Gissen P, Baruteau J. Clinical applications for exosomes: Are we there yet?. Br J Pharmacol 2021 · PMID 33751579
- US Food and Drug Administration. Public Safety Notification on Exosome Products.. FDA notification, 6 December 2019
Exosomes — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Exosomes — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Exosomes moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Exosomes in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Exosomes
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Exosomes — frequently asked questions
What is Exosomes?
Exosomes (Extracellular vesicles (EVs), MSC-conditioned media, plant exosomes) is a healing & recovery research compound. Exosomes are nanoscale (30–150 nm) lipid-bilayer vesicles that cells release to talk to each other. They carry a cargo — miRNA, mRNA, proteins, lipids — and when a neighboring cell takes one up, that cargo changes what the recipient cell does. The cosmetic premise is that vesicles harvested from stem-cell-conditioned media or from plants deliver pro-regenerative signals to skin. The mechanism is real biology and is under serious investigation. The problem is not the concept, it is everything downstream of it.
Is the full Exosomes protocol on this page?
The reported research dose is on this page, along with how Exosomes works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Exosomes?
Exosomes has an approximate half-life of Not characterized for topical products, which is part of what determines how often it's dosed.
What's the evidence behind Exosomes?
Current evidence level: Preclinical and in-vitro; no standardized human topical evidence. Regulators have warned about unapproved injectable exosome products.. Exosomes is offered for research purposes only and is not an approved medicine.
What Exosomes is used for
Exosomes appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.